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signaling as a driver for refractive error
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Abstract
Refractive errors, including myopia, are the most frequent eye disorders worldwide and an 
increasingly common cause of blindness. This genome-wide association meta-analysis in 160,420 
participants and replication in 95,505 participants, increased the established independent signals 
from 37 to 161 and revealed high genetic correlation between Europeans and Asians (>0.78). 
Expression experiments and comprehensive in silico analyses identified retinal cell physiology and 
light processing as prominent mechanisms, and functional contributions to refractive error 
development in all cell types of the neurosensory retina, retinal pigment epithelium, vascular 
endothelium and extracellular matrix. Newly identified genes elicited novel mechanisms such as 
rod and cone bipolar synaptic neurotransmission, anterior segment morphology, and angiogenesis. 
Thirty-one loci resided in or near regions transcribing small RNAs, suggesting a role for post-
transcriptional regulation. Our results support the notion that refractive errors are caused by a 
light-dependent retina-to-sclera signaling cascade, and delineate potential pathobiological 
molecular drivers.
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INTRODUCTION
Refractive errors are common optical aberrations determined by mismatches in the focusing 
power of the cornea, lens and axial length of the eye. Their distribution is rapidly shifting 
towards myopia, or nearsightedness, all over the world. The myopia boom is particularly 
prominent in urban East Asia where up to 95% of twenty-year-olds in cities such as Seoul 
and Singapore have this refractive error1–4. Myopia prevalence is also rising throughout 
Western Europe and the USA, affecting ~50% of young adults in these regions5,6. While 
refractive errors can be optically corrected, even at moderate values they carry significant 
risk of ocular complications with high economic burden7–9. One in three individuals with 
high myopia (−6 diopters or worse) will develop irreversible visual impairment or blindness, 
mostly due to myopic macular degeneration, retinal detachment, or glaucoma10,11. At the 
other extreme, high hyperopia predisposes to strabismus, amblyopia and angle-closure 
glaucoma10,12.
Refractive errors result from a complex interplay of lifestyle and genetic factors. The most 
established lifestyle factors for myopia are high education, lack of outdoor exposure, and 
excessive near work3. Recent research has identified many genetic variants for refractive 
errors, myopia, and axial length13–25. Two large studies, the international Consortium for 
Refractive Error and Myopia (CREAM)26 and the personal genomics company 23andMe, 
Inc.17,27 have provided the most comprehensive results.28
Given that only 3.6% of the variance of the refractive error trait was explained by the 
identified genetic variants26, we presumed a high missing heritability. We therefore 
combined CREAM and 23andMe, and expanded the study sample to 160,420 individuals 
from a mixed ancestry population with quantitative information on refraction for a genome-
wide association (GWAS) meta-analysis. Index variants were tested for replication in an 
independent cohort consisting of 95,505 individuals from the UK Biobank. We conducted 
systematic comparisons to assess differences in genetic inheritance and distribution of risk 
variants between Europeans and Asians. Polygenic risk analyses were performed to evaluate 
the contribution of the identified variants to the risk of myopia and hyperopia. Finally, we 
integrated expression data and bioinformatics on the identified genes to gain insight into the 
possible mechanisms underlying the genetic associations.
RESULTS
Susceptibility loci for refractive error
We performed a GWAS meta-analysis on adult untransformed spherical equivalent (SphE) 
using summary statistics from 37 studies from CREAM and on age of diagnosis of myopia 
(AODM) from two cohorts from 23andMe (Supplementary Figure 1, Supplementary Table 
1a)26,27. Analyses were based on ~11 million genetic variants (SNPs, insertions and 
deletions) genotyped or imputed to 1000 Genomes Project Phase I reference panel (version 
3, March 2012 release29) that passed extensive quality control (Supplementary Figures 2–4, 
Supplementary Table 1b).
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Meta-analyses were conducted in three stages: Stage 1 CREAM (CREAM-EUR, N=44,192; 
CREAM-ASN, N=11,935); Stage 2 23andMe (N=104,293; Online Methods); Stage 3 joint 
meta-analysis of Stage 1 and 2. As CREAM and 23andMe applied different phenotype 
measures, we used signed Z-scores as the mean per-allele effect size and assigned equal 
weights to CREAM and 23andMe. We identified 7,967 genome-wide significant genetic 
variants clustering in 140 loci (Figure 1a,b; Supplementary Figure 5–6, Supplementary Table 
2-5, Supplementary Data 1-2), replicating all 37 previously discovered loci and finding 104 
novel loci. We applied genomic control at each stage and checked for population 
stratification using LD score regression30 (Stage 1-2 inflation factors ( ?GC) <1.1 and LD 
score regression intercepts (LDSCintercept) 0.892-1.023; Supplementary Table 6; 
Supplementary Figure 6-7). At Stage 3, we observed a genomic inflation ( ?GC=1.129; 
Supplementary Figure 6), probably due to true polygenicity rather than population 
stratification or cryptic relatedness31. LDSCintercept remained undetermined due to mixed 
ancestry.
To detect the presence of multiple independent signals at the discovered loci, a stepwise 
conditional analysis was performed with GCTA-COJO32 on summary statistics from all 
European cohorts (N=148,485) using the Rotterdam Study I-III (RS I-III) as a reference 
panel for LD structure (NRSI-III=10,775). This analysis yielded 27 additional independent 
variants, resulting in a total of 167 loci (Supplementary Table 2).
We advanced these loci for replication in a GWAS of refractive error carried out by the UK 
Biobank Eye & Vision (UKEV) Consortium (N=95,505)33 (Online Methods). Six out of the 
167 variants were not considered for replication analysis. One of these five variants 
(rs3138141, RDH5) was identified previously and therefore still considered as a refractive 
error risk variant26,27. The remaining 161 genetic variants were tested for replication. 86% 
(138/161) of the candidate variants replicated significantly: 104 (65%) replicated surpassing 
genome-wide significance and 34 replicated surpassing Bonferroni correction (P<3.0×10−4; 
21.1%); another 12 showed nominal evidence for replication (0.05<P<3.0×10−4; 7.5%) and 
only 11 (7%) did not replicate at all (Table 1, Supplementary Table 2).
As CREAM and 23andMe employed different phenotypic outcomes, we evaluated 
consistency of genotypic effects by comparing marker-wise additive genetic effect sizes (in 
units diopters per risk allele variant) for SphE from CREAM-EUR against those (in units 
log(HR) per risk allele variant) for AODM from 23andMe. All variants strongly associated 
with either outcome (P<0.001) were concordant in direction-of-effect, and had highly 
correlated effect sizes (Figure 2a,b; Supplementary Figure 8). For these variants a 10% 
decrease in log(HR) for AODM, indicating an earlier age-at-myopia onset, was associated 
with a decrease of 0.15 diopters in SphE. A quantitative analysis for all common SNPs 
(MAF>0.01; HapMap3) using LD score regression yielded a genetic correlation of 0.93 
(95% CI 0.86-0.99; P=2.1×10−159), confirming that effect sizes for both phenotypic 
outcomes were closely related.
Gene annotation of susceptibility loci
We annotated all genetic variants with wANNOVAR using the University of California 
Santa Cruz (UCSC) Known Gene database34,35. The identified 139 genetic loci were 
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annotated to 208 genes and known transcribed RNA genes (Table 1, Supplementary Table 2, 
Online Methods). The physical positions of the lead genetic variants relative to protein-
coding genes are shown in Figure 1c. 86% of the identified variants were either intragenic or 
less than 50 kb from the 5ᓉor 3ᓉend of the transcription start site. We found seven exonic 
variants (Supplementary Table 7) of which two had MAF≤0.05: rs5442 (GNB3) and 
rs17400325 (PDE11A). The index SNP in the GNB3 locus with MAF 0.05 in Europeans is a 
highly conserved missense variant (G272S) predicted to be damaging by PolyPhen-236 and 
SIFT37. PDE11A is presumed to play a role in tumorigenesis, brain function, and 
inflammation38. The index SNP in the PDE11A locus with MAF 0.03 in Europeans is also a 
highly conserved missense variant (Y727C); this variant was predicted to be damaging by 
PolyPhen36, SIFT39 and align GVGD40,41.The other exonic variants, rs1064583 
(COL10A1), rs807037 (KAZALD1), rs1550094 (PRSS56), rs35337422 (RD3L), and 
rs6420484 (TSPAN10) were not predicted to be damaging.
The most significant variant (Stage 3; rs12193446, P=4.21×10−84) resides on chromosome 6 
within a non-coding RNA, BC035400, in an intron of the LAMA2 gene. This locus had been 
identified previously, but our current fine mapping redefined the most associated variant. 
The function and potential downstream target sites for BC035400 are currently unknown. 
The previously most strongly associated variant, rs524952 on chromosome 15 near GJD2, 
was the second most significant variant (P=2.28×10−65).
Post-GWAS analyses
We performed two gene-based tests, fastBAT42 and EUGENE43, and applied a functional 
enrichment approach using fgwas44 (Online Methods). With fastBAT, we identified 13 genes 
at P <2.0×10−6, one of which (CHD7) had been identified previously26,27. Using EUGENE, 
we found 7 genes at P <2.0×10−6 after incorporation of blood eQTLs. With fgwas, we 
identified 6 loci, which could be annotated to 9 genes, at posterior probability >0.9. Two 
genes (HMGN4 and TLX1) showed significant associations in two or more approaches. 
Taken together, these post-GWAS approaches resulted in a total of 22 additional candidate 
loci for refractive error, annotated to 25 genes (Supplementary Table 8). This increases the 
overall number of significant genetic associations to 161 candidate loci.
Polygenic risk scores
We calculated polygenic risk scores (PGRS)45 per individual at various P thresholds (Online 
Methods) for Rotterdam Study I-III (RS I-III; N=10,792) after recalculating P and Z-scores 
of variants from Stage 3 excluding RS I-III. We found the highest fraction of phenotypic 
variance (7.8%) explained with 7,307 variants at P value threshold 0.005 (Supplementary 
Table 9). A PGRS based on these variants distinguished well between individuals with 
hyperopia and myopia at the lower and higher deciles (Figure 3); those in the highest decile 
had a 40-fold increased risk of myopia. When the PGRS was stratified for the median age 
(<63 or >63+ yrs), we found a significant difference in the variance explained (<63 yrs 
8.9%; 63+ yrs 7.4%; P 0.0038). The variance explained by PGRS was not significantly 
different between males and females (8.3% vs 7.5%; P 0.13). The predictive value (area 
under the receiver operating characteristic curve, AUC) of the PGRS for myopia versus 
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hyperopia adjusted for age and gender was 0.77 (95% CI=0.75–0.79), a 10% increase 
compared to previous estimations46.
Trans-ethnic comparison of genotypic effects
To explore potential ancestry differences in the identified refractive error loci, we calculated 
the heritability explained by common genetic variants (SNP-h2) for Europeans and Asians 
using LD score regression47. SNP-h2 was 0.214 (95% CI 0.185- 0.243) and 0.172 (95% CI 
0.154- 0.190) in the European samples (CREAM-EUR and 23andMe), while it was only 
0.053 (95% CI -0.025- 0.131) in the Asian sample (CREAM-EAS). Next, we estimated the 
genetic correlation between Europeans and Asians by comparing variant effect size for 
common variants using Popcorn48 (Online Methods). Two genetic correlation metrics were 
calculated T; First, a genetic effect correlation ( ?ge) that quantifies the correlation in SNP 
effect sizes between Europeans and Asians without taking into account ancestry-related 
differences in allele frequency; and second, a genetic impact correlation ( ?gi) that estimates 
the correlation in variance-normalized SNP effect sizes between the two ancestry groups 
(Table 2). Estimates of  ?ge were high between Europeans and Asians, but significantly 
different from 1 (0.79 and 0.80, respectively at P <1.9×10−6; Table 2), indicating a clear 
genetic overlap but a difference in per allele effect size. Estimates of  ?gi were similarly high 
(>0.8), but not significantly different from 1 for the correlation between CREAM-EUR and 
CREAM-ASN (P=0.065), indicating that the genetic impact of these alleles may still be 
similar.
In silico pathway analysis
We used an array of bioinformatics tools to investigate potential functions and pathways of 
the associated genes. We first employed DEPICT49 to perform a gene set enrichment 
analysis, a tissue type enrichment, and a gene prioritization analysis, on all variants with P 
<1.00×10−5 from Stage 3. The gene set enrichment analysis resulted in 66 reconstituted gene 
sets, of which 55 (83%) were eye-related. To reduce redundancies between pathways, we 
clustered the significant pathways into 13 meta gene sets (false discovery rate (FDR) <5% 
and a P <0.05) (Supplementary Note 2, Figure 4, Supplementary Table 10). The most 
significant gene set was the ‘ abnormal photoreceptor inner segment morphology’  (MP:
0003730; P=1.79×10−7). The eye-related meta gene sets consisted of the ‘ thin retinal outer 
nuclear layer’  (MP:0008515; 27 (55%) gene sets), ‘ detection of light stimulus’  (GO:
0009583; 13 (24%) gene sets), ‘ nonmotile primary cilium’  (GO:0031513; 4 (6%) gene sets), 
and ‘ abnormal anterior eye segment morphology’  (MP:0005193; 4 (6%) gene sets). The first 
three meta gene sets had a Pearson’ s correlation > 0.6. Interestingly, RGR, RP1L1, RORB 
and GNB3 were present in all of these meta gene sets. Retina was the most significant tissue 
of expression according to the tissue enrichment analysis (P=1.11 × 10−4, FDR <0.01). From 
the gene prioritization according to DEPICT, 7 genes were highlighted as the most likely 
causal genes at P<7.62×10−6 and FDR<0.05: ANO2, RP1L1, GNB3, EDN2, RORB and 
CABP4.
Next, we performed a canonical pathway analysis on all genes annotated to the variants of 
Stage 3 using Ingenuity Pathway Analysis (See URLs). All genes were run against the IPA 
database incorporating functional biological evidence on genomic and proteomic expression 
Tedja et al. Page 7
Nat Genet. Author manuscript; available in PMC 2018 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
based on regulation or binding studies. IPA identified “Glutamate Receptor Signaling” with 
central player Nf-kB gene as the most significant pathway after correction for multiple 
testing (ratio of the number of molecules 8.8% and Fisher’ s Exact test P=1.56×10−4; 
Supplementary Figure 9).
From disease-associated loci to biological mechanisms
We adapted the scoring scheme designed by Fritsche et al.50 to highlight genes for which 
there is biological plausibility for a role in eye growth50. We used 10 equally rated 
categories (Online Methods; Figure 5; Supplementary Table 11; Supplementary Note 2). 
One-hundred-and-nine index variants replicated in two or more individual cohorts; we found 
evidence for seven genetic variants with eQTL effects in multiple tissue types; nine exonic 
variants, of which seven predicted protein-alterations (Supplementary Table 7); 31 RNA 
genes, five located in the 3ᓉor 5ᓉUTR (Supplementary Table 12, Supplementary Figure 10), 
84 genes resulting in an ocular phenotype in humans (Supplementary Table 13) and 36 in 
mice (Supplementary Table 14); 172/212 (81%) genes expressed in human ocular tissue 
(Supplementary Note 2, Supplementary Table 15); 41 genes identified by DEPICT at P 
<5.4×10−4 and FDR<0.05 and 45 genes contributed to the most significant canonical 
pathways of IPA. Notably, 48 of the associated genes encode known drug targets 
(Supplementary Table 16).
The gene with the highest biological plausibility score (score=8) was GNB3, a highly 
conserved gene encoding a guanine nucleotide-binding protein expressed in rod and cone 
photoreceptors and ON-bipolar cells51. GNB3 participates in signal transduction through G-
protein-coupled receptors and enhances the temporal accuracy of phototransduction and ON-
center signaling in the retina51. As described above, the index SNP harbors a missense 
variant associated with refractive errors. Non-synonymous mutations within GNB3 are 
known to cause syndromic congenital stationary night blindness52 in humans, progressive 
retinopathy and globe enlargement in chickens51, and abnormal development of the 
photoreceptor-bipolar synapse in knock-out mice53,54.
Other genes highly ranked (score=7) include CYP26A1, GRIA4, RDH5, RORB, and RGR, 
all previously associated with refractive error, and one newly identified gene: EFEMP1. 
EFEMP1 encodes a member of the fibulin family of extracellular matrix glycoproteins, and 
is found pan-ocularly including in the inner nuclear layer and Bruch’ s membrane. Mutations 
in this gene lead to specific macular dystrophies55, while variants have also been shown to 
co-segregate with primary open-angle glaucoma56 and associate with optic disc cup area57.
Several other genes are noteworthy for their function. CABP4, a calcium-binding protein 
expressed in cone and rod photoreceptor cells, mediates Ca2+-influx and glutamate release in 
the photoreceptor-bipolar synapse58. Mutations in this gene have been described in 
congenital cone-rod synaptic disorder59, a retinal dystrophy associated with nystagmus, 
photophobia, and, remarkably, high hyperopia. KCNMA1 encodes pore-forming alpha 
subunits of Ca2+-activated K+ (BK) channels. These channels regulate synaptic transmission 
exclusively in the rod pathway60. ANO2 is a Ca2+-activated Cl− channel recently reported to 
regulate retinal pigment epithelial (RPE) cell volume in a light-dependent manner64. EDN2 
is a potent vasoconstrictor that binds to two G-protein-coupled receptors, EDNRA, which 
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resides on bipolar dendrites, and EDNRB, which is present on Mueller and horizontal cells. 
Both receptors are also present on choroidal vessels65, implying that the choroid as well as 
retinal cells are target sites for this gene. RP1L1 is expressed in cone and rod photoreceptors 
where it is involved in the maintenance of microtubules in the connecting cilium66. 
Mutations in this gene cause dominant macular dystrophy and retinitis pigmentosa67. We 
replicated two genes known to cause myopia in family studies. FBN1 harbors mutations 
causing with Marfan (OMIM #154700) and Weil Marchesani (OMIM #608328) syndrome; 
PTPRR was one of the candidates in the MYP3 locus, which was found by linkage in 
families with high myopia68.
The location of rs7449443 (P=3.58×10−8) is notable as it resides in between DRD1 and 
FLJ16171. DRD1 encodes dopamine receptor 1 and is known to modulate dopamine 
receptor 2-mediated events69,70. The dopamine pathway has been implicated in myopia 
pathogenesis in many studies69,71. SNPs in and near other genes involved in the dopamine 
pathway (dopamine receptors, synthesis, degradation, and transporters)72–74 did not reveal 
genome-wide significant associations (Supplementary Note 3, Supplementary Table 17; 
Supplementary Figure 11).
There were 31 genetic variants in or near DNA structures transcribing RNA genes (non 
coding RNA, linc RNAs, tRNAs, snoRNas, rRNAs). Notably, five were in the transcription 
region and thirteen were in the vicinity (>0 kb and ≤50 kb) of start or end of the RNA gene 
transcription region. They received low scores, since many have no reported function or 
disease association to date (Figure 5, Supplementary Figure 10, Supplementary Table 12). 
Our ranking of genes based on functional information existing in the public domain does not 
necessarily represent the true order of importance for refractive error pathogenesis. The 
observation that genes with strong statistical association were distributed over all scores 
supports this concept. Nevertheless, this list may help to select genes for subsequent 
functional studies.
Finally, integration of all our findings, supported by literature, allowed us to annotate a large 
number of genes to ocular cell types (Figure 6). Remarkably, all cell types of the retina 
harbored refractive error genes, as well as the RPE, vascular endothelium, and extracellular 
matrix.
Genetic pleiotropy
We performed a GWAS catalogue look up using FUMA to investigate overlap of genes with 
other common traits (Supplementary Figure 12)75. Refractive error and hyperopia were 
replicated significantly after correcting for multiple testing (adjusted P value=1.44×10−52 
and 9.34×10−9, respectively). We found significant overlap with 74 other traits, of which 
height (adjusted P value=1.11×10−10), obesity (adjusted P=1.38×10−10), and BMI (adjusted 
P=4.05×10−7) were most important. Ocular diseases significantly associated were glaucoma 
(optic cup area, intraocular pressure; adjusted P=2.69×10−5 and 3.01×10−5, respectively) and 
age-related macular degeneration (adjusted P value=1.27×10−3).
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DISCUSSION
Myopia may become the leading cause of world blindness in the near future, a grim outlook 
for which current counteractions are still insufficient11,76. To improve understanding of the 
genetic landscape and biology of refractive error, we conducted a large GWAS meta-analysis 
in 160,420 participants of mixed ancestry and replicated in 95,505 participants. This led to 
the identification of 139 independent susceptibility loci by single variant analysis and 22 
additional loci through post-GWAS methods, a four-fold increase in refractive error genes. 
The majority of annotated genes were found to be expressed in the human posterior segment 
of the eye. Using in silico analysis, we identified significant biological pathways, of which 
retinal cell physiology, light processing, and, specifically, glutamate receptor signaling were 
the most prominent mechanisms. Our integrated bio-informatic approach highlighted known 
ocular functionality for many genes.
To ensure robustness of our genetic associations, we included studies of various designs and 
populations, sought replication in an independent cohort of significant sample size, and 
stringently accounted for population stratification by performing genomic control at all 
stages of the meta-analysis77. We combined studies with outcomes based on actual refractive 
error measurements as well as on self-reported age-of-myopia-onset, and found the 
direction-of-effect of the associated variants, as well as their effect size, to be remarkably 
consistent. Combining two different outcome measures may appear unconventional, but age 
of onset and refractive error have been shown to be very tightly correlated11,28,78,79. 
Moreover, the high genetic correlation (93%) of common SNPs between the two phenotypes 
underscores their similarity. Most compelling evidence was provided by replication of 86% 
of the discovered variants in the independent UKEV which also used conventional refractive 
error measurements. This robustness indicates that both phenotypic outcomes can be used to 
capture a shared source of genetic variation. In addition, we found trans-ethnic replication of 
significant loci, and a high correlation of genetic effects of common variants in the 
Europeans and Asians. Our findings support a largely shared genetic predisposition to 
refractive error and myopia in the two ethnicities, although ancestry-specific allelic effects 
may exist. The low heritability estimate in Asians may, in part, be explained by the low 
representation of this ethnicity in our study sample. Alternatively, it may imply that 
environmental factors explain a greater proportion of the phenotypic risk and recent rise in 
myopia prevalence in this ancestry group80.
Limitations of our study were the possibility of false negative findings due to genomic 
control, and underrepresentation of studies with Asian ancestry. Heterogeneity of observed 
effect estimates was large for several associated variants, but not unexpected, given the large 
number of collaborating studies with varying methodology.
Although neurotransmission was previously suggested pathway26,27, our current pathway 
analyses provide more in-depth insights into the retinal circuitry driving refractive error. 
DEPICT identified ‘ thin retinal outer nuclear layer’ , ‘ detection of light stimulus’ , and 
‘ nonmotile primary cilium’  as the most important meta-gene sets. These are the main 
characteristics of photoreceptors, which are located in the outer retina and contain cilia. 
These photosensitive cells drive the phototransduction cascade in response to light, which in 
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turn induces visual information processing. IPA pointed towards glutamate receptor 
signaling as the most significant pathway. Glutamate is released by photoreceptors and 
determines conductance of retinal signaling to the ON and OFF bipolar cells81. Our 
functional gene look ups provide evidence that rod (CLU) as well as cone (GNB3) bipolar 
cells play a role. Taken together, these findings strongly suggest that light response and light 
processing in the retina are initiating factors leading to refractive error.
The genetic association with light-dependent pathways may also link to the well-established 
protective effect of outdoor exposure on myopia. We found suggestive evidence for a genetic 
association with DRD1. The dopaminergic pathway has been studied extensively in animal 
models for its role in controlling eye growth in response to light69,71,82–91. DRD1 was found 
to be a mediator in this process, as bright light increased DRD1 activity in the bipolar ON-
pathway, and diminished form-deprivation myopia in mice. Blockage of DRD1 reversed this 
inhibitory effect92. We did not find evidence for direct involvement of other genes in the 
dopamine pathway, but GNB3 may be an indirect modifier as it is a downstream signaling 
molecule of dopamine and has been shown to influence availability of the dopamine 
transporter DAT93. Although a promising target for therapy, further evidence of DRD1 in 
human myopiagenesis is warranted.
Novel pathways elicited by the newly identified genes are anterior segment morphology 
(TCF7L2, VIPR2, MAF) and angiogenesis (FLT1). In addition, the high number of variants 
residing near small RNA genes suggests that post-transcriptional regulation is an important 
mechanism, as these RNAs are known to play a distinct and central regulatory role in cells94. 
These findings will serve as leads for future studies performing detailed mapping of cellular 
networks, and functional studies on genes implicated in ocular phenotypes, harboring 
protein-altering variants, and proven drug targets.
Our evaluation of shared genetics between refractive error and other disease-relevant 
phenotypes highlighted overlap with anthropometric traits such as height, obesity, and body 
mass index. This could give valuable additional clues as to the phenotypic outcomes of 
perturbations of some of the networks identified.
Our genetic observations add credence to the current notion that refractive errors are caused 
by a retina-to-sclera signaling cascade that induces scleral remodeling in response to light 
stimuli. The concept of this cascade originates from various animal models showing that 
form deprivation, retinal defocus and contrast, ambient light, and wavelength can influence 
eye growth in young animals95–97. Cell-specific moieties in this putative signaling cascade 
in humans were largely unknown, although animal models implicated GABA, dopamine, all-
trans-retinoic acid and TGF- ?69,91,98,99. Our study provides a large number of new 
molecular candidates for this cascade, and clearly shows that a wide range of neuronal cell 
types in the retina, the RPE, the vascular endothelium, as well as components of the 
extracellular matrix are implicated. The many interprotein relationships exemplify the 
complexity of eye growth, and provide a challenge to develop strategies to prevent 
pathological eye elongation.
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In conclusion, by using a cross-ancestry design in the largest study population on common 
refractive errors to date, we uncovered numerous novel loci and pathways involved in eye 
growth. Our multi-disciplinary approach incorporating GWAS data with in silico analyses 
and expression experiments provides an example for the design of future genetic studies for 
complex traits. Additional genetic insights into refractive errors will be gained by increasing 
sample size and genotyping depth, by performing family studies to identify rare alleles of 
large effects, and by evaluating population extremes. Our list of plausible genes and 
pathways provide a plethora of data for future studies focusing on gene-environment 
interaction, and on translation of GWAS findings into starting points for therapy.
ONLINE METHODS
Ethics Statement
All human research was approved by the relevant institutional review boards and conducted 
according to the Declaration of Helsinki. All CREAM participants provided written 
informed consent; all 23andMe applicants provided informed consent online, and answered 
surveys according to 23andMe’ s human subjects protocol, which was reviewed and 
approved by Ethical & Independent Review Services, an AAHRPP-accredited institutional 
review board. The UK Biobank received ethical approval from the National Health Service 
National Research Ethics Service (reference 11/NW/0382).
Study data
The study populations were participants of the Consortium for Refractive Error and Myopia 
(CREAM) comprising of 41,793 individuals with European ancestry from 26 cohorts 
(CREAM-EUR) and 11,935 individuals with Asian ancestry from 8 studies (CREAM-ASN); 
and customers of the 23andMe genetic testing company who gave informed consent for 
inclusion in research studies consisting of 104,293 individuals (2 cohorts of individuals with 
European ancestry, N = 12,128 and N= 92,165, respectively). All participants included in 
this analysis from CREAM and 23andMe were aged 25 years or older. Participants with 
conditions that could alter refraction, such as cataract surgery, laser refractive procedures, 
retinal detachment surgery, keratoconus as well as ocular or systemic syndromes were 
excluded from the analyses. Recruitment and ascertainment strategies varied per study 
(Supplementary Table 1a,b, and Supplementary Note 4). Refractive error represented by 
measurements of refraction and analyzed as spherical equivalent (SphE =spherical refractive 
error + 1/2 cylinder refractive error) was the outcome variable for CREAM; myopic 
refractive error represented by self-reported age of diagnosis of myopia (AODM) for 
23andMe27.
Genotype calling and imputation
Samples were genotyped on different platforms and study specific quality control measures 
of the genotyped variants were implemented before association analysis (Supplementary 
Table 1b). Genotypes were imputed using the appropriate ancestry-matched reference panel 
for all cohorts from the 1000 Genomes Project (Phase I version 3, March 2012 release) with 
either minimac100 or IMPUTE101. The metrics for pre-imputation quality control varied 
amongst studies, but genotype call rate thresholds were set at high level (≥0.95 for both 
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CREAM and 23andMe). These metrics were similar to our previous GWAS analyses26,27; 
details per cohort can be found in Supplementary Table 1b.
GWAS per study
For each CREAM cohort, a single marker analysis for the SphE (in diopters) phenotype was 
carried out using linear regression adjusting for age, sex and up to the first five principal 
components. All non-family-based cohorts removed one of each pair of relatives (after 
detection using either GCTA or IBS/IBD analysis). In family-based cohorts, a score test-
based association was used to adjust for within-family relatedness102. For the 23andMe 
participants, Cox proportional hazards analysis testing AODM as the dependent variable 
were performed as previously described27, with P calculated using a likelihood ratio test for 
the single marker genotype term. We used an additive SNP allelic effect model for all 
analyses.
Centralized quality control per study
After individual GWAS, all studies underwent a second round of quality control (QC). 
Quantile-quantile, effect allele frequency, P – Z test, standard error – sample size, and 
genomic control inflation factor plots were generated for each individual cohort using 
EasyQC103 (Supplementary Figure 2.1 (Supplementary Figure 2.1.1 and 2.1.2), 2.2 
(Supplementary Figure 2.2.1 – 2.2.5), 2.3 (Supplementary Figure 2.3.1 and 2.3.2). All 
analytical issues discovered during this QC step were resolved per individual cohort.
GWAS meta-analyses
The GWAS meta-analyses were performed in three stages (Supplementary Figure 1). In 
Stage 1, European (CREAM-EUR, N=44,192) and Asian (CREAM-ASN, N=11,935) 
participants from the CREAM cohort were meta-analysed separately. Subsequently, all 
CREAM cohorts (CREAM-ALL) were meta-analysed. Variants with MAF < 1% or 
imputation quality score < 0.3 (info metric of IMPUTE) or Rsq < 0.3 (minimac) were 
excluded. A fixed effects inverse variance-weighted meta-analysis was performed using 
METAL104. 1,063 variants clustering in 24 loci (Supplementary Table 2) were genome-wide 
significant (P=5.0×10−8). All 37 loci that were previously found by CREAM and 23andMe 
using genotype data imputed to the HapMap II reference panel were replicated (pBonferroni 
1.85×10−3), and 36 of the 37 were genome-wide significant (Supplementary Table 2)26,27. In 
Stage 2, a meta-analysis of the two 23andMe cohorts (N23andMe_V2=12,128; 
N23andMe_V3=92,165) was performed, using similar filtering but a lower MAF threshold (< 
0.5%). A total of 5,205 genome-wide significant variants clustered in 112 loci 
(Supplementary Table 2).
In Stage 3, CREAM-ALL and 23andMe samples were combined using a fixed effects meta-
analysis based on P value and direction of effect. In all stages, each genetic variant had to be 
represented by at least half of the entire study population and at least represented by 13 
cohorts in CREAM and one cohort in 23andMe. For SNPs with high heterogeneity (at P < 
0.05), we also performed a random effects meta-analysis using METASOFT50. We chose a 
different weighting scheme due to the differences in effect size scaling; 23andMe used a less 
accurate phenotype variable (AODM); i.e. the effective sample size of the 23andMe was 
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approximately equivalent to the effective sample size of CREAM-ALL (Figure 2b), thus 
weighting by (1/√neffective) yielded a final weighting ratio of 1:1105. Genome-wide statistical 
significance was defined at P < 5.0 × 10−8 106.
All three meta-analysis stages were performed under genomic control. Study specific and 
meta-analysis lambda ( ?) estimates are shown in Supplementary Figure 6; to check for 
confounding biases (e.g. cryptic relatedness and population stratification), LD score 
intercepts from LD score regressions per ancestry were constructed (Supplementary Figure 
7)30. To check the robustness of signals, we performed a conventional random effects 
models using METASOFT, fixed effects models weighted on sample size and on weights 
estimated from standard error per allele tested using METAL (Supplementary Table 2 and 
Supplementary Table 3).
Manhattan (modified version of package ‘ qqman’ ), regional, box, and forest plots were 
made using R version 3.2.3 and LocusZoom107. An overview of the Hardy Weinberg P of all 
index variants per cohort can be found in Supplementary Table 4. The comparison between 
refractive error and age-of-onset was performed using the LDSC program30.
Population stratification and heritability calculations
Each study assessed the degree of genetic admixture and stratification in their study 
participants through the use of principal components. Homogeneity of participants was 
assured by removal of all individuals whose ancestry did not match the prevailing ancestral 
group. We used genomic inflation factors to control for admixture and stratification, and 
performed genomic-controlled meta-analysis to account for the effects of any residual 
heterogeneity. To further distinguish between inflation from a true polygenic signal and 
population stratification, we examined the relationship between test statistics and linkage 
disequilibrium (LD) with LDSC. CREAM-EUR, CREAM-ASN and 23andMe were 
evaluated separately; variants not present in HapMap3 and MAF < 1% were excluded. SNP 
heritability estimates were calculated using LDSC for the same set of genetic variants.
Locus definition and annotation
All study effect size estimates were oriented to the positive strand of the NCBI Build 37 
reference sequence of the human genome. The index variant of a locus was defined as the 
variant with the lowest P in a region spanning a 100 kb window of the most outer genome-
wide significant variant of that same region. We annotated all index variants using the web-
based version of ANNOVAR108 based on UCSC Known Gene Database35. For variants 
within the coding sequence or 5ᓉor 3ᓉuntranslated regions of a gene, that gene was 
assigned to the index variant (note that this led to more than 1 gene being assigned to 
variants located within the transcription units of multiple, overlapping genes). For variants in 
intergenic regions, the nearest 5ᓉgene and the nearest 3ᓉgene were assigned to the variant. 
Index variants were annotated to functional RNA elements when described as such in the 
UCSC Known Gene Database. We used conservation (PhyloP109) and prediction tools 
(SIFT39, Mutation Taster110, align GVGD40,41, PolyPhen-236) to predict the pathogenicity 
of protein-altering exonic variants.
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Conditional signal analysis
We performed conditional analysis to identify additional independent signals nearby the 
index variant at each locus, using GCTA-COJO32. We transformed the Z-scores of the 
summary statistics to beta’ s using the following formula: 
Standard Error = 1/2 ∗ N ∗ MAF 1 − MAF . We performed the GCTA-COJO analysis32, 
utilizing summary-level statistics from the meta-analysis on all cohorts. Linkage 
disequilibrium (LD) between variants was estimated from the Rotterdam Study I-III.
Replication in UK Biobank
The UK Biobank Eye & Vision (UKEV) Consortium performed a GWAS of refractive error 
in 95,505 participants of European ancestry aged 37-73 year with no history of eye 
disorders33. Refractive error was measured using an autorefractor; SphE was calculated per 
eye and averaged between the two eyes. To account for relatedness a mixed model analysis 
with BOLT-LMM was used111, including age, gender, genotyping array, and the first 10 
principal components as covariates. Analysis was restricted to markers present on the HRC 
reference panel112. We performed lookups for all independent genetic variants identified in 
our Stage 3 meta-analysis and conditional analysis. For 16 variants not present in UKEV, we 
performed lookups for a surrogate variant in high LD (r2 >0.8). When more than one 
potential surrogate variant was available, the variant in strongest LD with the index variant 
was selected. Six variants were not available for replication: one variant (rs188159083) was 
not present on the array nor was a surrogate available in UKEV and five variants showed 
evidence of departure from HWE (HWE exact test P<3.0×10−4).
Post-GWAS analyses
We performed two gene-based tests to identify additional significant genes not found in the 
single variant analysis. First, we applied the gene-based test implemented in fastBAT42 to 
the per-variant summary statistics of the meta-analysis of all European cohorts (23andMe 
and CREAM-EUR). We used the default parameters (all variants in or within 50kb of a 
gene) and focused on variants with a gene-based P <2 × 10−6 (Bonferroni correction based 
on 25,000 genes) and the per-variant P >5 × 10−8. Secondly, we applied another gene-based 
test in EUGENE43 which only includes variants which are eQTLs (GTex, blood113). 
EUGENE tests an hypothesis predicated on eQTLs as key drivers of the association signal. 
eQTLs within 50kb of a gene were included in the test. Genes with EUGENE P <2 × 10−6 
(and not found in the single variant analysis) were considered to be significant. Finally, we 
used functional annotation information from genome-wide significant loci to reweigh results 
using fgwas (version 0.3.6444). Fgwas incorporates functional annotation (e.g. DNase I-
hypersensitive sites in various tissues and 3ᓉUTR regions) to reweight data from GWAS, and 
uses a Bayesian model to calculate a posterior probability of association. This approach is 
able to identify risk loci that otherwise might not reach the genome-wide significance 
threshold in standard GWAS. Details about this approach can be found in Supplementary 
Note 5.
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Refractive errors and myopia risk prediction
To assess the risk of the entire range of refractive errors, we computed polygenic risk scores 
(PGRS) for the population-based Rotterdam Studies (RS) I, RS-II and RS-III using the P and 
Z scores from a meta-analysis on CREAM-ALL and 23andMe, excluding the RS I-III 
cohorts. Only variants with high imputation quality (IMPUTE info score > 0.5 or minimac 
Rsq > 0.8) and MAF > 1% were considered. P-based clumping was performed with 
PLINK114, using an r2 threshold of 0.2 and a physical distance threshold of 500 kb, 
excluding the MHC region. This resulted in a total of 243,938 variants. For each individual 
in RS-I, RS-II and RS-III (N = 10,792), PGRS were calculated using the –score command in 
PLINK across strata of P thresholds: 5.0 × 10−8, 5.0 × 10−7, 5.0 × 10−6, 5.0 × 10−5, 5.0 × 
10−4, 0.005, 0.01, 0.05, 0.1, 0.5, 0.8 and 1.0. The proportion of variance explained by each 
PGRS model was calculated as the difference in the R2 between two regression models; one 
where SphE was regressed on age, sex, the first five principal components, and the other also 
including the PGRS as an additional covariate. Subsequently, AUCs were calculated for 
myopia (SphE ≤ -3 SD) versus hyperopia (SphE ≥ +3 SD).
Genetic correlation between ancestries
We used Popcorn48 to investigate ancestry-related differences in the genetic architecture of 
refractive error and myopia. Popcorn takes summary GWAS statistics from two populations 
and LD information from ancestry-matched reference panels, and computes genetic 
correlations by implementing a weighted likelihood function that accounts for the inflation 
of Z scores due to LD. Pairwise analyses were carried out using the GWAS summary 
statistics from 23andMe (N = 104,292), CREAM-EUR (N = 44,192) and CREAM-EAS (N 
= 9,826) meta-analyses. Only SNPs with MAF ≥ 5% were included, resulting in a final set 
of 3,625,602 SNPs for analyses involving 23andMe and 3,642,928 SNPs for the CREAM-
EUR versus CREAM-EAS analysis. Reference panels were constructed using genotype data 
from 503 European and 504 East Asian individuals sequenced as part of the 1000 Genomes 
Project (release 2013-05-02 downloaded from: ftp.1000genomes.ebi.ac.uk). The reference 
panel VCF files were filtered using PLINK114 to remove indels, strand-ambiguous variants, 
variants without an “rs” id prefix, and variants located in the MHC region on chromosome 6 
(chr6:25,000,000-33,500,000; Build 37).
Analysis between phenotypes
To evaluate consistency of genotypic effects across studies that employed different 
phenotype definitions, we compared effect sizes from GWAS studies of either SphE or 
AODM in Europeans, i.e. CREAM-EUR (N = 44,192) or 23andMe (N = 104,293) 
respectively. Marker-wise additive genetic effect sizes (in units diopters per copy of the risk 
allele) for SphE were compared against those (in units log(HR) per copy of the risk allele) 
for AODM. Data was visualised using R. Genetic correlation between the two phenotypes 
SphE and AODM was calculated using LD score regression. This analysis included all 
common SNPs (MAF > 0.01) present in HapMap3.
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Evidence for functional involvement
In order to rank genes according to biological plausibility, we scored annotated genes based 
on our own findings and published reports for a potential functional role in refractive error. 
Points were assigned for each gene on the basis of 10 categories (details on the methodology 
per category are provided in Supplementary Note 4): internal replication of index genetic 
variants in the individual cohort GWAS analyses through Bonferroni corrections (CREAM-
ASN, CREAM-EUR and 23andMe; pBonferroni 1.19 × 10−4), evidence for eQTL using the 
FUMA32 and extensive look-ups in GtEx, evidence of expression in the eye in 
developmental and adult ocular tissues, presence of an eye phenotype in knock-out mice 
(MGI and IMPC database), presence of an eye phenotype in humans (OMIM; see URLs, 
DisGeNET115), location in a functional region of a gene (wANNOVAR; see URLs), 
presence of the gene in a significant enriched functional pathway with false discovery rate < 
0.05 (DEPICT49), presence of the gene in the gene priority analysis of DEPICT with false 
discovery rate < 0.05 and the presence of the gene in the canonical pathway analysis of 
Ingenuity Pathway Analysis (IPA; See URLs). Furthermore, we performed a systematic 
search for each gene to assess its potential as a drug target (SuperTarget116, STITCH117, 
DrugBank118, PharmaGkb119). All information derived from this study and literature were 
used to annotate genes to retinal cell types.
Genetic pleiotropy
To investigate overlap of genes with other common traits, we performed a look-up in the 
GWAS catalog using FUMA. Multiple testing correction (i.e. Benjamini-Hochberg) was 
performed. Traits were significantly associated when adjusted P ≤ 0.05 and the number of 
genes that overlap with the GWAS catalog gene sets was ≥ 2.
Data availability statement—The summary statistics of the Stage 3 meta-analysis are 
included in Supplementary Data 3 of this published article. In order to protect the privacy of 
the participants in our cohorts, further summary statistics of Stage 1 (CREAM) and Stage 2 
(23andMe) will be available upon request. Please contact c.c.w.klaver@erasmusmc.nl 
(CREAM) and/or apply.research@23andMe.com (23andMe) for more information and to 
access the data.
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Figure 1. GWAS meta-analysis identifies 140 loci for refractive error (Stage 3)
(a) We conducted a meta-analysis of genome-wide single-variant analyses for >10 million 
variants in 160,420 participants of CREAM and 23andMe (Stage 3). Shown is the 
Manhattan plot depicting P for association, highlighting new (P < 5 × 10−8 for the first time; 
green) and known (dark grey) refractive error loci previously found using HapMap II 
imputations from Kiefer et al.27 and Verhoeven et al.26 (Table 1). The horizontal lines 
indicate suggestive significance (P=1×10−5) or genome-wide significance (P=5×10−8). (b) 
We compared the minor allele frequencies of the 140 discovered index variants based on 
1000G (blue: Europeans; red: Asians) to the minor allele frequencies of the previously found 
genetic variants based on HapMap II (green: Europeans; purple: Asians). Observed are an 
increase in genetic variants found across all minor allele frequency bins increase, including 
the lower minor allele frequency bins. (c) We annotated the 167 loci to genes using 
wANNOVAR. Shown are the distances between index variants from the nearest gene and its 
gene on the 5ᓉand/or 3ᓉsite. The majority of index variants (84%) were at a distance of 
less than 50 kb up- or downstream from the annotated gene.
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Figure 2. Correlation of statistical significance and effect size of SNPs based on spherical 
equivalent (SphE) in diopters and age of diagnosis of myopia (AODM) in years
(a) P comparison of all genetic variants with P < 1.0 × 10−3 (n=7249) between CREAM 
meta-analysis (Stage 1) and 23andMe (Stage 2) meta-analysis. Shown is the overlap (red) 
and the difference (green) in P signals per cohort for genetic variants. Green genetic variants 
are only genome wide significant in either CREAM or 23andMe. Blue: genetic variants with 
P between 5.0 × 10−8 and 1.0 × 10−3 in both CREAM and 23andMe. (b) Comparison of 
effects (SphE and logHR of AODM in years; P < 1.0 × 10−3; n=7249) between CREAM and 
23andMe. Same color code was applied as in (a). The effects were concordant in their 
direction of effect on refractive error. We performed a simple linear regression between the 
effects of CREAM and 23andMe; the regression slope is -0.15 diopters per logHR of 
AODM in years.
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Figure 3. Risk of refractive error per decile of polygenic risk score (Rotterdam Study I-III, 
N=10,792)
Distribution of refractive error in subjects from Rotterdam Study I–III (N=10,792) as a 
function of the optimal polygenic risk score (including 7,303 variants at P ≤ 0.005 
explaining 7.8% of the variance of SphE; Supplementary Table 9). Mean OR of myopia 
(black line) was calculated per polygenic risk score category using the lowest category as a 
reference. High myopia (SphE ≤-6 D), moderate myopia (SphE >-6 D & ≤ −3 D), low 
myopia (SphE > −3 D & <-1.5 D), emmetropia (SphE ≥ −1.5 D and ≤ 1.5 D), low hyperopia 
(SphE > 1.5 D & < 3 D), moderate hyperopia (SphE ≥ 3 D & 6 D), high hyperopia (SphE ≥ 
6 D).
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Figure 4. Visualization of the DEPICT gene-set enrichment analysis based on loci associated with 
refractive error and the correlation between the (meta)gene sets
(a) Shown are the 66 significantly enriched reconstituted gene sets clustered into thirteen 
meta gene sets based on the gene set enrichment analysis of DEPICT (pairwise Pearson 
correlations; P < 0.05). All genetic variants with a P < 1 × 10−5 in the GWAS meta-analysis 
of stage 3 (n=21,073) and an FDR < 0.05 were considered. (b) Visualization of the 
interconnectivity between gene sets (n=13; pairwise Pearson correlations; P < 0.05) of the 
meta gene set ‘ Detection of Light Stimulus’  (GO:0009583). (c) Visualization of the 
interconnectivity between gene sets (n=27; pairwise Pearson correlations; P < 0.05) of the 
largest meta gene set ‘ Thin Retinal Outer Nuclear Layer’  (MP:0008515). In all panels, 
(meta)gene sets are represented by nodes colored according to statistical significance, and 
similarities between them are indicated by edges scaled according to their correlation; 
Pearson’ s r ≥ 0.2 are shown in panel (a) and Pearson’ s r ≥ 0.4 are shown in panel (b,c).
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Figure 5. Genes ranked according to biological and statistical evidence
Genes were ranked (orange) based on 10 equal categories which can be divided in four 
categories: internal replication of genetic variant in more than two cohorts (purple; CREAM-
EUR, CREAM-ASN and/or 23andMe), annotation (light blue; genetic variant harboring an 
exonic protein altering variant or non-protein altering variant, genetic variant residing in a 5ᓉ
or 3ᓉUTR region of a gene or transcribing an RNA structure), expression (yellow; eQTL, 
expression in adult human ocular tissue, expression in developing ocular tissue), biology 
(dark yellow; ocular phenotype in mice, ocular phenotype in humans), pathways (green; 
DEPICT gene-set enrichtment, DEPICT gene prioritization analysis and canonical pathway 
analysis of IPA). We assessed genes harboring drug targets (salmon red), but did not assign a 
scoring point to this category.
*Only one point can be assigned in the category ‘ ANNOTATION’ , even though it has four 
columns (i.e. a genetic variant is located in only 1 of these four categories).
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Figure 6. Schematic representation of the human eye, retinal cell types, and functional sites of 
associated genes
We assessed gene expression sites and/or functional target cells in the eye for all genes using 
our expression data and literature and data present in the public domain. The genes appear to 
be distributed across virtually all cell types in the neurosensory retina, in the RPE, vascular 
endothelium and extracellular matrix; i.e., the route of the myopic retina-to-sclera signalling 
cascade.
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Table 1
Results of the meta-analysis of CREAM and 23andMe for the previously-identified loci and a subset of the newly-identified loci, and replication in UK Biobank
a Replication of the HapMap II index variants for refractive error per locus in the Stage 3 meta-analysis
SNP Chr Position Nearest Loci And
Gene(s)
Effect
Allele
Other
Allele
EAF
EUR
EAF
ASN
Z-score Direction P value HetISq HetPVal Sample
Size (N)
HapMap II
Discovery (2013)
Category P value
Replication
rs10500355 16 7459347 RBFOX1 A T 0.354 0.133 −13.73 −− 6.49E-43 9.1 2.93E-07 160,139 Kiefer et al. & Verhoeven et al. I 2.50E-48
rs11145465 9 71766593 TJP2 A C 0.212 NA −9.55 −− 1.35E-21 46.3 0.1722 153,174 Kiefer et al. & Verhoeven et al. I 1.00E-10
rs11178469 12 71275137 PTPRR T C 0.752 0.638 −7.40 −− 1.33E-13 0 0.6989 160,139 Verhoeven et al. II (CREAM) 2.60E-04
rs11602008 11 40149305 LRRC4C A T 0.822 0.749 13.98 ++ 2.12E-44 22.5 1.56E-10 157,505 Kiefer et al. II (23andMe) 2.90E-47
rs12193446 6 129820038 BC035400, LAMA2 A G 0.906 NA −19.43 −− 4.21E-84 16.8 5.72E-15 150,269 Kiefer et al. & Verhoeven et al. I 4.60E-106
rs1550094 2 233385396 CHRNG, PRSS56 A G 0.701 0.705 12.74 ++ 3.64E-37 26.3 0.003 159,422 Kiefer et al. & Verhoeven et al., Kiefer et al. I 4.10E-59
rs1649068 10 60304864 BICC1 A C 0.475 0.504 −9.44 −− 3.77E-21 0 0.712 160,144 Verhoeven et al. I 7.50E-11
rs17382981 10 94953258 CYP26A1,MYOF T C 0.417 0.190 −6.31 −− 2.72E-10 67.9 0.077 155,332 Verhoeven et al. II (CREAM) 4.10E-07
rs17428076 2 172851936 HAT1, METAP1D C G 0.768 0.854 −8.18 −− 2.77E-16 0 0.003 160,151 Kiefer et al. II (23andMe) 7.50E-08
rs1858001 1 207488004 C4BPA,CD55 C G 0.676 0.415 7.28 ++ 3.45E-13 59.6 0.020 160,149 Verhoeven et al. II (CREAM) 6.70E-20
rs1954761 11 105596885 GRIA4 T C 0.371 0.377 −8.40 −− 4.57E-17 0 0.911 160,122 Verhoeven et al. I 1.20E-16
rs2155413 11 84634790 DLG2 A C 0.482 0.655 −7.76 −− 8.85E-15 0 2.99E-04 159,504 Kiefer et al. II (23andMe) 1.10E-17
rs235770 20 6761765 BMP2 T C 0.372 0.388 −5.93 −− 3.11E-09 0 0.547 157,521 Verhoeven et al. II (23andMe) 4.80E-11
rs2573081 2 178828507 PDE11A C G 0.524 0.538 8.21 ++ 2.18E-16 47.6 0.167 160,126 Kiefer et al. II (23andMe) 1.60E-29
rs2753462 14 60850703 JB175233, C14orf39 C G 0.296 0.568 −6.49 −− 8.37E-11 73.9 0.050 157,352 Verhoeven et al. II (CREAM) 2.00E-15
rs2855530 14 54421917 BMP4 C G 0.507 0.474 −8.58 −− 9.87E-18 41.7 0.190 160,092 Kiefer et al. I 4.80E-22
rs2908972 17 11407259 SHISA6 A T 0.415 0.484 −11.13 −− 9.46E-29 23 0.254 160,123 Kiefer et al. & Verhoeven et al. I 6.10E-29
rs3138141 12 56115778 BLOC1S1-RDH5,RDH5 A C 0.214 0.147 13.80 ++ 2.46E-43 3.2 5.05E-07 157,531 Kiefer et al. & Verhoeven et al. I 2.30E-56
rs4687586 3 53837971 CACNA1D C G 0.691 NA −6.55 −− 5.86E-11 0 0.605 150,217 Verhoeven et al. III 1.60E-08
rs4793501 17 68718734 KCNJ2, BC039327 T C 0.575 0.444 −7.21 −− 5.53E-13 0 0.592 160,150 Verhoeven et al. II (CREAM) 3.70E-12
rs524952 15 35005886 GOLGA8B, GJD2 A T 0.475 0.507 −17.08 −− 2.28E-65 67.2 0.015 160,150 Kiefer et al. & Verhoeven et al. I 1.60E-103
rs56075542 2 146882415 BC040861, PABPC1P2 T G 0.552 0.472 −8.99 −− 2.39E-19 13.9 0.001 159,478 Kiefer et al. II (23andMe) 1.30E-18
rs62070229 17 31227593 MYO1D, TMEM98 A G 0.807 0.874 8.58 ++ 9.64E-18 0 0.416 156,570 Verhoeven et al. I 1.30E-18
rs6495367 15 79375347 RASGRF1 A G 0.408 0.399 −10.20 −− 1.95E-24 0 0.667 160,144 Kiefer et al. & Verhoeven et al. I 7.20E-37
rs7042950 9 77149837 RORB A G 0.732 0.392 6.80 ++ 1.07E-11 0 0.912 160,153 Verhoeven et al. III 2.90E-18
rs72621438 8 60178580 SNORA51, CA8 C G 0.642 0.609 −13.14 −− 2.03E-39 38.4 0.006 160,128 Kiefer et al. & Verhoeven et al. I 1.80E-49
rs745480 10 85986554 LRIT2,LRIT1 C G 0.511 0.418 8.31 ++ 9.26E-17 67.3 0.081 159,504 Kiefer et al. II (23andMe) 8.20E-18
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a Replication of the HapMap II index variants for refractive error per locus in the Stage 3 meta-analysis
SNP Chr Position Nearest Loci And
Gene(s)
Effect
Allele
Other
Allele
EAF
EUR
EAF
ASN
Z-score Direction P value HetISq HetPVal Sample
Size (N)
HapMap II
Discovery (2013)
Category P value
Replication
rs7624084 3 141093285 ZBTB38 T C 0.568 0.633 −8.81 −− 1.24E-18 18.5 0.018 160,151 Kiefer et al. II (23andMe) 6.50E-17
rs7662551 4 80537638 LOC100506035, PCAT4 A G 0.723 0.558 8.53 ++ 1.47E-17 19.4 0.265 160,147 Verhoeven et al. I 6.00E-12
rs7692381 4 81903049 C4orf22, BMP3 A G 0.763 0.630 9.40 ++ 5.55E-21 0 0.013 160,134 Kiefer et al. I 7.50E-13
rs7744813 6 73643289 KCNQ5 A C 0.591 0.602 −14.56 −− 5.43E-48 35 0.001 160,091 Kiefer et al. & Verhoeven et al. I 1.00E-75
rs7829127 8 40726394 ZMAT4 A G 0.792 0.897 −10.91 −− 1.02E-27 15.9 2.77E-04 160,132 Kiefer et al. & Verhoeven et al. II (23andMe) 3.10E-22
rs7895108 10 79061458 KCNMA1 T G 0.351 0.118 −8.87 −− 7.56E-19 32.8 0.021 160,140 Kiefer et al. II (23andMe) 1.10E-27
rs79266634 16 7309047 RBFOX1 C G 0.093 0.115 −5.93 −− 3.00E-09 0 0.561 156,268 Kiefer et al. & Verhoeven et al. III 1.50E-08
rs837323 13 101175664 PCCA T C 0.512 0.762 6.32 ++ 2.65E-10 35.6 0.213 160,142 Verhoeven et al. II (23andMe) 5.30E-16
rs9517964 13 100717833 ZIC2,PCCA T C 0.589 0.786 8.42 ++ 3.68E-17 0 0.020 160,121 Kiefer et al. II (23andMe) 3.40E-20
b Subset of the new loci harboring the smallest p-values for refractive error in the Stage 3 meta-analysis
SNP Chr Position Nearest Loci And
Gene(s)
Effect
Allele
Other
Allele
EAF
EUR
EAF ASN Z-score Direction P value HetISq HetPVal Sample
Size (N)
Category P value
Replication
rs36024104 14 42294993 LRFN5 A G 0.823 NA 9.09 ++ 9.86E-20 15.9 0.01414 152,585 II (23andMe) 2.20E-12
rs7456039 7 6901710 CCZ1B, LOC100131257 C G 0.183 NA 8.82 ++ 1.18E-18 42.1 3.79E-12 121,337 II (23andMe) 6.50E-01
rs1556867 1 164213686 5S_rRNA, PBX1 T C 0.264 0.494 −8.81 −− 1.29E-18 71.1 0.06266 160,155 II (23andMe) 4.20E-17
rs12667032 7 154406581 DPP6 A G 0.152 0.317 7.99 ++ 1.31E-15 82.3 1.02E-11 130,790 II (23andMe) 2.10E-01
rs2225986 1 200311910 LINC00862 A T 0.381 0.169 −7.96 −− 1.68E-15 40.2 0.196 160,152 II (23andMe) 7.50E-17
rs1207782 6 22059967 LINC00340 T C 0.577 0.265 −7.92 −− 2.47E-15 0 0.8946 160,149 I 4.90E-13
rs72826094 10 114801488 TCF7L2 A T 0.799 0.838 7.88 ++ 3.20E-15 64.5 0.09323 156,825 II (23andMe) 4.90E-02
rs297593 2 157363743 GPD2 T C 0.286 0.257 −7.82 −− 5.45E-15 0 0.5285 159,461 II (23andMe) 7.80E-11
rs5442 12 6954864 GNB3 A G 0.068 NA −7.82 −− 5.48E-15 8.8 0.03693 146,217 II (23andMe) 1.20E-33
rs10880855 12 46144855 ARID2 T C 0.507 0.464 −7.78 −− 7.35E-15 0 0.9683 160,144 I 4.80E-08
rs12405776 1 242431557 PLD5 T C 0.220 0.521 7.75 ++ 9.52E-15 64.9 3.56E-10 153,784 II (23andMe) 1.50E-01
rs2150458 21 47377296 PCBP3, COL6A1 A G 0.455 0.641 7.74 ++ 1.04E-14 55.7 0.1329 160,151 II (23andMe) 1.80E-13
rs12898755 15 63574641 APH1B A G 0.245 0.456 7.53 ++ 4.98E-14 7.9 0.2974 159,506 II (23andMe) 1.40E-16
rs7122817 11 117657679 DSCAML1 A G 0.507 0.662 7.51 ++ 5.73E-14 73.8 0.05077 160,147 II (23andMe) 1.10E-10
rs10511652 9 18362865 SH3GL2, ADAMTSL1 A G 0.416 0.445 7.36 ++ 1.91E-13 44.8 0.1782 160,149 II (23andMe) 3.50E-18
rs11101263 10 49414181 FRMPD2 T C 0.258 0.105 −7.33 −− 2.33E-13 0 0.3477 160,155 II (23andMe) 2.20E-13
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b Subset of the new loci harboring the smallest p-values for refractive error in the Stage 3 meta-analysis
SNP Chr Position Nearest Loci And
Gene(s)
Effect
Allele
Other
Allele
EAF
EUR
EAF ASN Z-score Direction P value HetISq HetPVal Sample
Size (N)
Category P value
Replication
rs11118367 1 219790221 LYPLAL1 T C 0.482 0.630 −7.29 −− 3.16E-13 0 0.8576 160,141 III 1.20E-13
rs9395623 6 50757699 TFAP2D, TFAP2B A T 0.315 0.381 7.25 ++ 4.16E-13 0 0.9579 160,151 III 2.20E-10
rs284816 8 53362145 ST18, FAM150A A G 0.163 0.198 −7.21 −− 5.52E-13 0 0.9242 160,140 III 1.60E-08
rs12965607 18 47391025 MYO5B T G 0.857 0.923 7.07 ++ 1.52E-12 20.8 0.01674 157,604 II (23andMe) 8.10E-16
rs7747 4 80827062 ANTXR2 T C 0.202 0.093 7.03 ++ 2.05E-12 5.4 0.01267 150,327 II (23andMe) 7.70E-16
rs12451582 17 54734643 NOG, C17orf67 A G 0.369 0.308 7.02 ++ 2.22E-12 0 0.5925 160,155 II (23andMe) 8.80E-18
rs80253120 17 14138507 CDRT15 T C 0.626 0.723 6.97 ++ 3.25E-12 58.6 0.12 156,054 II (23andMe) 7.20E-11
22:23069851:I 22 23069851 DKFZp667J0810 ATG A 0.084 0.1582 6.95 −+ 3.56E-12 98.5 4.80E-16 120,481 II (23andMe) 9.30E-01
rs7968679 12 9313304 PZP A G 0.700 0.894 6.95 ++ 3.65E-12 0 0.01951 160,076 II (23andMe) 4.20E-10
rs11202736 10 90142203 RNLS A T 0.717 0.762 −6.92 −− 4.53E-12 0 0.4007 160,150 II (23andMe) 9.40E-07
rs11088317 21 16574122 NRIP1, USP25 T C 0.287 0.299 −6.90 −− 5.38E-12 72.5 0.05657 160,116 II (23andMe) 6.50E-06
rs10853531 18 42824449 SLC14A2 A G 0.200 0.182 6.88 ++ 5.89E-12 0 0.6755 160,104 III 2.60E-10
rs72655575 8 60556509 SNORA51, CA8 A C 0.201 0.124 6.87 ++ 6.54E-12 0 0.8811 156,566 I 7.10E-07
rs12998513 2 242879499 CXXC11,AK097934 A G 0.880 0.676 −6.86 +− 7.15E-12 65.2 4.51E-14 117,611 II (23andMe) 7.80E-01
rs1790165 11 131928971 NTM A C 0.411 0.283 6.85 ++ 7.17E-12 0 0.003708 160,131 II (23andMe) 1.80E-10
rs511217 11 30029948 METTL15, KCNA4 A T 0.738 0.729 −6.79 −− 1.10E-11 0 0.3626 160,143 II (23andMe) 1.40E-17
rs1150687 6 28162469 ZNF192P1, TRNA_Ser T C 0.619 0.504 6.78 ++ 1.17E-11 56.2 0.131 159,448 II (23andMe) 3.10E-10
rs56055503 16 80532694 MAF, DYNLRB2 A G 0.751 0.539 −6.72 −− 1.83E-11 0 0.8407 160,145 II (23andMe) 8.00E-06
rs9681162 3 8194734 AK124857, LMCD1-AS1 T C 0.680 0.437 6.70 ++ 2.10E-11 63 0.1002 160,152 II (23andMe) 6.30E-13
rs11589487 1 61342229 AK097193, BC030753 A G 0.445 0.089 6.67 ++ 2.64E-11 34.6 0.2163 160,143 II (23andMe) 2.20E-10
We identified 140 loci for refractive error with genome-wide significance (P < 5 × 10−8) on the basis the meta-analyses of the genome-wide single-variant linear regressions performed in 160,420 participants of mixed ancestries (CREAM-ASN, CREAM-EUR and 23andMe). 
Shown are the replication of the previously found loci from HapMap II and a subset of the new loci harboring the smallest P values. For each locus, represented by an index variant (the variant with smallest p-value in that locus), Effect Allele, Other Allele, effect allele 
frequencies per ancestry (EAF AZN and EAF EUR), effect size (Z-score), direction of the effect (Direction), the P value, heterogeneity I square (HetISq), heterogeneity P value (HetPval), Sample Size (N), Category (I = both GWS in Stage 1 and 2, 2=one of two cohorts 
(CREAM or 23andMe) GWS, 3= both not GWS in Stage 1 or 2) and P value of the replication in UK Biobank are shown (Full table: Supplementary Table 2). Chr, chromosome; EAF, effect allele frequency; ASN, Asian; EUR, European; GWS, genome wide significant.
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Table 2
Genetic correlation for refractive error between Europeans and East Asians
Sample 1 Sample 2 Genetic effect correlation (pge) a Standard error pge P value pge Genetic impact correlation (pgi) a Standard error pgi P value pgi
EUR CREAM EAS CREAM 0.804 0.041 1.83E-06 0.888 0.061 0.065
EUR 23andMe EAS CREAM 0.788 0.041 2.48E-07 0.865 0.054 0.014
Abbreviations: EUR, European; EAS, East Asian.
a
P-value relates to a test of the null hypothesis that pge=1 or pgi=1.
We calculated the genetic correlation of effect (pge) and impact (pgi) using Popcorn to compare the genetic associations between Europeans (CREAM-EUR, N= 44,192; 23andMe, N=104,292) and East 
Asians (CREAM-ASN, N= 9,826). Reference panels for Popcorn were constructed using genotype data for 503 EUR and 504 EAS individuals sequenced as part of the 1000 Genomes Project. SNPs used 
had a MAF of at least 5% in both populations, resulting in a final set of 3,625,602SNPs for the analyses using the 23andMe GWAS sample and 3,642,928 SNPs for those using the CREAM-EUR sample. 
These findings support a largely common genetic predisposition to refractive error and myopia in Europeans and Asians, although ancestry-specific risk alleles may exist.
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